Indication
Ovarian High Grade Serous Adenocarcinoma
Aliases
Unresectable Ovarian High Grade Serous Adenocarcinoma
18 clinical trials
21 products
6 drugs
Clinical trial
A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial CancerStatus: Recruiting, Estimated PCD: 2026-04-30
Product
ZEN-3694Product
TuvusertibClinical trial
A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-01
Product
AbemaciclibProduct
OlaparibClinical trial
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2023-05-09
Drug
AtezolizumabClinical trial
Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805Status: Recruiting, Estimated PCD: 2024-06-30
Drug
AN0025Clinical trial
A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor TherapyStatus: Withdrawn, Estimated PCD: 2023-03-17
Product
CopanlisibProduct
PaclitaxelProduct
TopotecanClinical trial
A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2026-12-31
Drug
AdavosertibProduct
IpatasertibDrug
TiragolumabClinical trial
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-30
Product
BerzosertibProduct
CarboplatinProduct
GemcitabineClinical trial
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2021-07-31
Product
TremelimumabClinical trial
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
AbraxaneClinical trial
FRαDCs Plus Pembrolizumab for Patients With Advanced Stage Ovarian CancerStatus: Recruiting, Estimated PCD: 2027-07-15
Product
PembrolizumabClinical trial
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2018-10-31
Product
CediranibClinical trial
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior BevacizumabStatus: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2022-07-07
Clinical trial
Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-06-30
Product
AtovaquoneClinical trial
Phase 1 Trial of Gemcitabine Combined With the Elimusertib (BAY 1895344) ATR Inhibitor With Expansion Cohorts in Advanced Pancreatic and Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
ElimusertibDrug
GemcitabineClinical trial
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-21
Product
Anetumab RavtansineClinical trial
A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2028-02-09
Product
TolinapantClinical trial
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)Status: Recruiting, Estimated PCD: 2024-09-01
Product
Peposertib